High quality raw material for IVD manufacturing industry

Recombinant spike S1 (RBD) antigen for COVID-19 (SARSCoV-2)

RekomBiotech
COVID-19 (SARSCoV-2)

Coronaviruses are enveloped viruses possessing large, trimeric spike glycoproteins (S) required for the recognition of host receptors for many coronaviruses as well as the fusion of viral and host cell membranes for viral entry into cells. During viral egress from infected host cells, some coronavirus S proteins are cleaved into S1 and S2 subunits. The S1 subunit is responsible for host-receptor binding while the S2 subunit contains the membrane-fusion machinery. Thus, S1 subunit contains the receptor-binding domain (RBD), located in the C-terminal region. This domain is used as a biomarker for COVID diagnostic.

View more information about Atypical pneumonia produced by COVID-19.

REFERENCES
COA RAG0074 new WB, DB, Indirect ELISA, positive control in direct ELISA, CLIA, lateral-flow
CCD SORBENT

As some human normal sera contains IgG antibodies against mannan from various pathogenic Candida species, they can interact with the CCD structures of the proteins produced in Pichia pastoris. With addition of this sorbent, the anti-CCD antibodies will be kidnapped, and the specificity of the assay will increase.

COASOR0001
GENE
S
DESCRIPTION
SARS-CoV-2 S1 Receptor Binding Domain (RBD)
PURITY
>95% in a SDS-PAGE
SHIPPING AND STORAGE CONDITIONS
Proteins will be shipped with dry ice or lyophilized. Upon arrival (if liquid), or after reconstitution (if lyophilized), they should be stored at -20ºC to -80ºC. Avoid multiple freeze/thaw cycles
STABILITY
The protein will remain stable for four years if stored frozen
SPECIFICITY
The protein is immunoreactive against seropositive individuals to Atypical pneumonia produced by COVID-19
IVD
COVID-19 serodiagnostic

FOR RESEARCH AND COMERCIAL USE IVD ONLY (*)

(*) Our antigens are provided for research and commercial use in vitro: not for human in vivo or therapeutic use. For more information about the general features of our antigens, you can visit here.

RETURN TO HUMAN RECOMBINANT ANTIGENS